

Anticipated First Time Generics in 2012

Brand Name	Common Uses	Manufacturer	2010 U.S. Retail Sales (millions)	Anticipated Availability*	
				Period	Year
Actoplus Met[®]	Diabetes	Takeda Pharmaceuticals	\$359	4th Quarter	2012
Actos[®]	Diabetes	Takeda Pharmaceuticals	\$2,631	3rd Quarter	2012
Atacand[®] & Atacand[®] HCT	Hypertension	AstraZeneca	\$181	4th Quarter	2012
Avalide[®]	Hypertension	Bristol-Myers Squibb	\$324	1st Quarter	2012
Avandamet[®]	Diabetes	GlaxoSmithKline	\$161	1st Quarter	2012
Avandia[®]	Diabetes	GlaxoSmithKline	\$269	1st Quarter	2012
Avapro[®]	Hypertension	Bristol-Myers Squibb	\$369	1st Quarter	2012
Diovan[®] & Diovan[®] HCT	Hypertension	Novartis	\$2,758	3rd Quarter	2012
Geodon[®]	Schizophrenia	Pfizer	\$959	3rd Quarter	2012
Lescol[®] & Lescol[®] XL	Cholesterol	Novartis	\$93	2nd Quarter	2012
Lexapro[®]	Depression	Forest Laboratories	\$2,483	1st Quarter	2012
Lidoderm[®]	Pain	Endo	\$934	4th Quarter	2012
Maxalt[®] & Maxalt-MLT[®]	Migraine Headache	Merck	\$453	4th Quarter	2012
Plavix[®]	Prevention of Blood Clots	Bristol-Myers Squibb	\$4,675	2nd Quarter	2012
Provigil[®]	Excessive Sleepiness	Cephalon	\$999	2nd Quarter	2012
Revatio[®]	Pulmonary Hypertension	Pfizer	\$178	3rd Quarter	2012
Seroquel[®]	Schizophrenia	AstraZeneca	\$3,222	1st Quarter	2012
Singulair[®]	Asthma/Allergies	Merck	\$3,324	3rd Quarter	2012
Tricor[®]	Cholesterol	Abbott Laboratories	\$1,015	2nd Quarter	2012
Viramune[®]	Antiretroviral	Boehringer Ingelheim	\$108	2nd Quarter	2012
Xopenex[®]	Asthma/COPD	Sunovion Pharmaceuticals	\$316	3rd Quarter	2012

* Anticipated availability is subject to change as a result of litigation, pediatric or other exclusivities.

Sources:

FDA, Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book) - *via on-line resources*
Drug Topics, Top 200 Brand-Name Drugs by Retail Dollars in 2010

Last Updated December 2011

www.theunadvertisedbrand.com



the unadvertised brand